Devonian Health Group Inc., a clinical stage corporation focused on developing unique solutions to inflammatory diseases, provides corporate update:
Thykamine: Pipeline Advances on Multiple Fronts
On the manufacturing front, batch-to-batch consistency of Thykamine has been validated through advanced analytical techniques, including High Performance Liquid Chromatography–Mass Spectrometry (HPLC-MS) and Nuclear Magnetic Resonance (NMR). These results highlight the robust quality and reliability of our production process for this first-in-class therapeutic.
Health Technology Insights: Zynex Names Steven Dyson CEO, Adds New Leadership
Pre-clinical programs are progressing to further demonstrate Thykamine’s unique dual action on both inflammation and fibrosis pathways. Current studies in Metabolic Associated Steatohepatitis (MASH) and pulmonary fibrosis models are designed to confirm its potential as a broadly applicable anti-inflammatory and anti-fibrotic drug. Data readouts are expected in fall 2025 and are anticipated to support expansion into multiple high-value indications.
In parallel, the company is advancing development of oral formulations (liquid and capsule) to unlock additional opportunities in Ulcerative Colitis and other diseases where oral delivery is preferred. This strategic diversification broadens Thykamine’s market reach and strengthens its long-term commercial potential.
Finally, a U.S. survey of dermatologists confirmed the acceptance of Thykamine cream in pediatric patients with mild-to-moderate atopic dermatitis, further supporting its clinical relevance and commercial potential. This positive outcome validates Devonian’s strategy to target this underserved population and further reinforces the commercial viability of Thykamine across multiple therapeutic areas.
Health Technology Insights: Tivic Health Advances Entolimod Talks at MHSRS 2025
Altius Healthcare LP
As announced on February 7, 2025, the distribution license for Dexlansoprazole was not renewed and officially expired on April 17, 2025. The Corporation has since been informed that the distribution agreement for Pantoprazole Magnesium — the second product licensed from the same partner, representing approximately 10.6% of revenues for the fiscal year ended July 31, 2024, and 4.2% for the nine-month period ended April 30, 2025 — will terminate on April 23, 2026. The Corporation will continue to market and sell Pantoprazole Magnesium until that date, maintaining revenue contributions in the interim. At the same time, management is carefully evaluating strategic options for this business unit.
Private Placement
On August 7, 2025, the Corporation announced the closing of a non-brokered private placement for aggregate gross proceeds of $2,272,999.85. The Corporation wishes to modify its press release to correct the information previously disclosed regarding the total gross proceeds, which was stated as $2,272,999.85, to reflect that it should have been $2,362,999.80 (the “Offering”). The Offering consisted of the issuance of 15,753,332 units (instead of the 15,153,332 units initially disclosed) of the Corporation (the “Units”) at a price of $0.15 per Unit. Each Unit is comprised of one common share of the Corporation (the “Shares”) and one Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one Share at an exercise price of $0.20 per Share for a period of 24 months from the date of issuance. All other information remains unchanged.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 15 August 2025
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- businesswire
